Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

Benzinga20:39

CMB International: Maintains INNOVENT BIO's "Buy" rating, with the Target Price raised to 57.67 HKD.

CMB International has released a research report stating that it maintains a "Buy" rating for INNOVENT BIO (01801), being bullish on the global potential of INNOVENT's Innovative Drugs pipeline, and has raised the target price to HKD 57.67 (previous value: HKD 55.21; WACC: 9.5%, perpetual growth rate: 3.5%). The company has licensed the global rights of the new DLL3ADC (IBI3009) to Roche, receiving an upfront payment of USD 80 million and up to USD 1 billion in milestone payments and sales sharing. The drug is expected to receive IND approval for global Phase 1 research in December 2024. Regarding the DLL3 target, besides

Sina Hong Kong Stocks16:36

Piper Sandler has lowered Amgen's Target Price to $310.

Gelonghui, January 2 | Piper Sandler: Downgraded Amgen's Target Price from $344 to $310, maintaining a "Shareholding" rating. (Gelonghui)

Gelonghui FinanceJan 2 23:30 · Ratings

After experiencing a bumper harvest in 2024, the USA ETF may encounter setbacks this year.

The USA Exchange Traded Fund (ETF) received a record inflow of $1.1 trillion in 2024, but entering 2025, rapid growth may face more obstacles.

Zhitong FinanceJan 2 20:49

Piper Sandler Initiates Amgen(AMGN.US) With Buy Rating, Announces Target Price $310

Futu NewsJan 2 20:32 · Ratings

Amgen Is Maintained at Overweight by Piper Sandler

Dow JonesJan 2 20:01 · Ratings